Case Report
Prucalopride and Varenicline (Champix): Case Report of a Possible Drug Interaction at Enteric Serotonin (5-HT) Receptors
Miss Molly Jakeman*, Kieran Moriarty and Suzanne Schneider
Bolton NHS Foundation Trust, United Kingdom
*Corresponding author: Miss Molly Jakeman, Bolton NHS Foundation Trust, Minerva Road, Farnworth, Bolton, BL4 0JR, United Kingdom
Published: 31 Oct, 2016
Cite this article as: Jakeman MM, Moriarty K, Schneider
S. Prucalopride and Varenicline
(Champix): Case Report of a Possible
Drug Interaction at Enteric Serotonin
(5-HT) Receptors. Ann Clin Case Rep.
2016; 1: 1175.
Abstract
Background: Prucalopride is a highly selective, high affinity agonist of serotonin (5-HT)4 receptors
on cholinergic motor neurones, and stimulates gastrointestinal motility through enhanced release
of acetylcholine. Prucalopride is approved for the treatment of Chronic Constipation (CC) in adult
women, for whom standard laxative use has failed to provide adequate relief.
Varenicline (Champix), prescribed as a smoking cessation aid, prevents nicotine stimulation of the
mesolimbic dopamine system associated with nicotine addiction. Varenicline is a highly selective,
high affinity partial agonist at neuronal α4β2 nicotinic receptors. It displays full agonism on a7/5-
HT3 nicotinic acetylcholine receptors and is a potent agonist of the human 5-HT3 receptor.
Case Presentation: Prucalopride treatment for an adult white female produced a marked, sustained
improvement in her chronic constipation. The benefit disappeared rapidly after commencing
varenicline, but was restored equally rapidly, once the varenicline was discontinued.
Conclusion: This case suggests a possible drug interaction between prucalopride and varenicline
at enteric 5-HT receptors. An interaction between these two medications has not previously been
described.
Keywords: Prucalopride; Varenicline; Serotonin; Receptors; Interaction; Case report
Introduction
Prucalopride stimulates the peristaltic reflex, colonic mass movements and colonic transit and
improves patient-reported outcomes in the treatment of Chronic Constipation (CC), namely bowel
movement frequency, bowel movement consistency, constipation-related quality of life (QOL) and
symptom scores and global assessments [1,2]. The improvement in patient satisfaction with bowel
habit and treatment is maintained during treatment for up to 24 months and prucalopride therapy
is generally safe and well tolerated in all age groups [1-3]. The National Institute for Health and
Clinical Excellence (NICE) Guidance [3] states that:
“Prucalopride is recommended as an option for the treatment of chronic constipation, only in
women for whom treatment with at least two laxatives, from different classes, at the highest tolerated
recommended doses, for at least six months, has failed to provide adequate relief, and invasive
treatment for constipation is being considered”.
Varenicline (Champix), prescribed for smoking cessation, interrupts signals of reward and
reinforcement of smoking by blocking the effect of nicotine on the mesolimbic dopamine system
[4]. The recommended dosage regime is 1mg twice daily for twelve weeks, following an initial
titration regime within the first week, starting at 0.5 mg once daily. A date for cessation of smoking
is scheduled by the user within the first two weeks of the treatment period [4]. In a meta-analysis of
101 studies of therapies for smoking cessation, varenicline proved more effective than bupropion
(odds ratio 1.40) and nicotine replacement therapies (odds ratio 1.56) [5].
An interaction between these drugs has not previously been described. A review of the
pharmacology and pharmacokinetics of both drugs indicates a potential for an interaction at enteric
5-HT receptors.
Case Presentation
A 57 year old white female presented with a 40 year history of refractory CC with distressing straining, bloating and nausea. She had tried many laxatives over
the years, and required 60 mg senna daily to open her bowels once
per week. Examination revealed mild abdominal distension. She was
commenced on prucalopride 2 mg daily. At review, four weeks later,
she reported an increase in bowel frequency from once per week to
opening her bowels every two to three days. Overall, she reported
approximately 75% improvement in her symptoms, describing it as
“a life-changing experience”. Prucalopride 2 mg daily was continued.
Ten weeks later, she was prescribed varenicline as a smoking
cessation aid, following a standard twelve week regime. Within 24-48
hours of starting the course, her symptoms of straining, bloating and
nausea returned, and within a week, her bowel frequency decreased,
virtually to the same frequency as prior to commencing prucalopride.
Two weeks later, she stopped smoking, but her symptoms persisted,
despite continuing prucalopride throughout. Since she was so
symptomatic, she discontinued varenicline after eight weeks but
continued to abstain from smoking.
Within 24-48 hours of stopping varenicline, her symptoms
and bowel frequency rapidly improved and the prucalopride effect
was fully restored. This improvement has been maintained from
discontinuation of varenicline until the present day.
Investigations
Routine investigations were ordered prior to a making a diagnosis
of CC. These included a full blood count, C-reactive protein, urea and
electrolytes, thyroid function tests, serum calcium, blood glucose,
liver function tests and tissue transglutaminase, which were all within
normal range.
Outcome
Prucalopride produced an improvement in bowel frequency and
a marked improvement in the symptoms and quality of life of our
patient. Following the discontinuation of varenicline, this has been
maintained until the present day.
Once a potential drug interaction was considered, an extensive
literature search of prucalopride, varenicline and their mechanisms of
action was conducted to determine if there was a previously reported
pharmacological basis for an interaction between the two drugs.
Discussion
Approximately 90% of the human body's total 5-HT is located in
the enterochromaffin cells in the gastrointestinal tract, where it plays
a key role in the regulation of gastrointestinal motility and secretions.
Disruption of 5-HT release within the gut can lead to alterations in
gut motility and is implicated in the pathogenesis of gastrointestinal
motility disorders, such as irritable bowel syndrome and CC [6].
Seven types of 5-HT receptors and numerous subtypes have been
described. 5-HT4 receptors are G-protein-coupled proteins, expressed
both in smooth muscle cells and in enteric neurones in the myenteric
plexus, which supplies motor innervation to both layers of the tunica
muscularis. Activation of these receptors both enhances acetylcholine
release in the longitudinal muscle layer and inhibits spontaneous
activity in the circular muscle layer. This contemporaneous
action enhances prokinetic pathways within the colon and leads
to synchronised, effective colonic propulsion [6,7]. Prucalopride
is a 5-HT4 agonist and its observed effects are exerted via highly
selective action at 5-HT4 receptors on cholinergic motor neurones,
with150-fold higher affinity for 5-HT4 receptors than it does for other receptors [7,9,10]. In vitro data indicate that prucalopride has a low
interaction potential, and therapeutic concentrations of prucalopride
are not expected to affect the CYP-mediated metabolism of comedicated
medicinal products [10]. Prucalopride is a weak substrate
for P-glycoprotein, but not an inhibitor at clinically relevant
concentrations [10,11].
Varenicline is a neuronal α4β2 nicotinic receptor partial agonist.
It has a higher affinity than nicotine for this receptor and thus blocks
the nicotinic effect on the mesolimbic dopamine system and thereby,
the signals for reward and reinforcement of smoking [4]. It also
displays full agonism on α7/5-HT3 nicotinic acetylcholine receptors,
and in vitro, at clinically relevant concentrations, binds to human
5-HT3 receptors, where it acts as a potent agonist [9]. 5-HT3 receptors
are found throughout the gut on vagal and mesenteric afferents. They
mediate visceral signals from the intestine to the central nervous
system, fast excitatory neurotransmission within the enteric nervous
system and stimulation of mucosal terminals of myenteric intrinsic
primary afferent neurons [6]. 5-HT3 antagonists inhibit the increase
in colonic tone after a meal in healthy humans and are efficacious
in the treatment of IBS-D (Diarrhoea-predominant Irritable Bowel
Syndrome) patients [12,13]. In addition, 5-HT3 antagonists can
be used to inhibit nociceptive signals transmitted to the central
nervous system as a result of visceral hypersensitivity, and are utilised
in the treatment of nausea and vomiting in patients undergoing
chemotherapy [6].
Prucalopride and varenicline both possess low pharmacokinetic
interaction potentials. They both have high affinity and selectivity
for their receptors and minimal effect on cytochrome P450 enzymes.
Varenicline and prucalopride are both well absorbed following oral
administration, their bioavailability unaffected by concomitant
intake of food and they are both excreted largely unchanged in the
urine [4,10,11,14].
Intriguingly, varenicline, as a 5-HT3 agonist, has also been
demonstrated to have an occasional anti-motility effect, being
associated with reports of constipation. A meta-analysis demonstrated
that, when used for more than 6 weeks at a dose of 1 mg twice
daily, there is an association between varenicline and constipation
(numbers needed to harm: 24) [15]. More understandable is the
significant association between varenicline and nausea (numbers
needed to harm: 5) [15]. Furthermore, 5-HT4 receptor agonists have
been shown to reduce nociceptive signals from the gastrointestinal
tract through mechanisms that are unclear [6,16].
Prucalopride and varenicline both have potential effects on
enteric nicotinic receptors. Acetylcholine release from the activation
of 5-HT4 receptors in the myenteric plexus in turn activates α7/5-HT3
nicotinic acetylcholine receptors on activated resident macrophages
within the sub-serosal and circular smooth muscle layers, to inhibit
their inflammatory reactions in the muscle layer of the intestine.
Under normal conditions in a healthy individual, these macrophages
are largely dormant and have been found to become activated
under certain conditions, such as following intestinal manipulation.
Varenicline displays full agonism on α7/5-HT3 nicotinic acetylcholine
receptors and it is therefore unlikely that the antagonistic effect
proposed in this case would be a result of interaction on nicotinic
receptors [17].
In the present case, prucalopride treatment for our patient
produced a marked, sustained improvement in her chronic constipation. The benefit disappeared rapidly after commencing
varenicline, but was restored equally rapidly, once the varenicline was
discontinued. The effect of prucalopride on bowel movements and
symptom relief has been maintained long term. While this case could
represent previously reported varenicline-associated constipation, we
know that varenicline is a potent 5-HT3 agonist and would therefore
be expected to cause diarrhoea. Furthermore, prucalopride would be
expected to enhance the pro-kinetic effect of varenicline, through its
action on 5-HT4 receptors. However, this is not the case in our patient
and leads to an interesting potential for a competing interaction or
modulation of the effect of these drugs on enteric 5-HT receptors.
Conclusion
This case highlights the importance of post-marketing
vigilance and surveillance of new medications. At the time of this
potential interaction, prucalopride was a new medication, acting
via a novel mechanism. This case explores the pharmacological
and pharmacokinetic mechanisms, in particular those related to
gastrointestinal 5-HT receptors, which are not as well recognised as
cholinergic or adrenergic mechanisms, in addition to the dual enzyme
systems, CYP-mediated and cytochrome P450, in the metabolism of
medicinal products.
We can only speculate as to whether this apparent antagonist
effect, with its rapid onset and offset, could have been due to an
interaction of prucalopride and varenicline on enteric 5-HT receptors.
Future clinical and pharmacological studies of the effects of 5-HT,
prucalopride and varenicline on gastrointestinal motility may help to
clarify the potential mechanisms of action of both drugs.
Consent
Written informed consent was obtained from the patient for publication of this case report. A copy of the written consent is available for review by the Editor of this journal.
Competing Interests
Declaration of personal interests: Dr Moriarty has served as an advisory board member, or received lecture fees or travel grants from SHIRE (manufacturers of prucalopride), Almirall, AstraZeneca, GlaxoSmithKline, Janssen, Johnson & Johnson and Warner Chilcott.
Authors’ Contributions
M. Jakeman: First draft of the manuscript and subsequent revisions. K. Moriarty: Patient selection and revisions to the manuscript. S. Schneider: Review of the pharmacological literature and contribution to manuscript revisions. All authors approved the final version of the manuscript.
Authors’ Information
KM is a Consultant Gastroenterologist, who has pioneered internationally-recognised, Gastroenterology, Liver, Psychiatry, Psychology, Pain Specialist holistic care, especially for socioeconomically-deprived, vulnerable patients with alcohol problems and disabling Abdominal Pain/Irritable Bowel Syndrome (IBS). He has published more than 100 papers, including many on bowel disorders, and written an Understanding Irritable Bowel Syndrome Patient Self-help Book (7th Edition 2013), which is sold worldwide.
Acknowledgement
We thank Paula Elliott, librarian Bolton NHS Foundation Trust, for assistance with the references.
References
- Shin A, Camilleri M, Kolar G, Erwin P, West CP, Murad MH. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag, naronapride) in chronic constipation. Aliment Pharmacol Ther. 2014; 39: 239-253.
- Camilleri M, Van Outryve MJ, Beyens G, Kerstens R, Robinson P, Vandeplassche L. Clinical trial: the efficacy of open-label prucalopride treatment in patients with chronic constipation-follow-up of patients from the pivotal studies. Aliment Pharmacol Ther. 2010; 32: 1113-1123.
- National Institute for Health and Clinical Excellence. Prucalopride for the treatment of chronic constipation in women. 2010.
- The electronic Medicines Compendium (eMC). Summary of product characteristics (SPC): CHAMPIX 0.5 mg film-coated tablets; CHAMPIX 1 mg film-coated tablets.
- Mills EJ, Wu P, Spurden D, Ebbert JO, Wilson K. Efficacy of pharmacotherapies for short-term smoking abstinence: a systematic review and meta-analysis. Harm Reduct J. 2009; 6: 25.
- Gershon MD. Review article: serotonin receptors and transporters - roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther. 2004; 20: 3-14.
- De Maeyer JH, Lefebvre RA, Schuurkes JA. 5-HT4 receptor agonists: similar but not the same. Neurogastroenterol Motil. 2008; 20: 99-112.
- Lummis SCR, Thompson AJ, Bencherif M, Lester HA. Varenicline is a Potent Agonist of the Human 5-Hydroxytryptamine3 Receptor. J Pharm Exp Ther. 2011; 339: 125-131.
- Briejer MR, Bosmans JP, Van Daele P, Jurzak M, Keylen L, Leysen JE, et al. The in vitro pharmacological profile of prucalopride, a novel enterokinetic compound. Eur J Pharmacol. 2001; 423: 71-83.
- The electronic Medicines Compendium (eMC). Summary of product characteristics (SPC): Resolor 1mg film-coated tablets.
- Stockley’s Drug Interactions. An interaction between prucalopride + miscellaneous.
- von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of postprandial colonic tonic and phasic responses in humans. Gut. 1994; 35: 536-541.
- Andresen V, Montori VM, Keller J, West CP, Layer P, Camilleri M. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 545-555.
- Lexicomp. Uptodate drug interactions.
- Leung LK, Patafio FM, Rosser WW. Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis. BMC Clin Pharmacol. 2011; 11: 15.
- Lyubashina OA, Busygina II, Panteleev SS, Nozdrachev AD. The 5HT4 receptor agonist prucalopride suppresses abdominal nociception. Dokl Biol Sci. 2015: 461: 76-79.
- Tsuchida Y, Hatao F, Fujisawa M, Murata T, Kaminishi M, Seto Y, et al. Neuronal stimulation with 5-hydroxytryptamine 4 receptor induces antiinflammatory actions via α7nACh receptors on muscularis macrophages associated with postoperative ileus. Gut. 2011; 60: 638-647.